Answers are grounded in this paper and cite their sources.
BACKGROUND: Hypertrophic scars (HS) are a challenging disorder that mostly develops during wound-healing process following skin injuries. METHODS: A split-scar, double-blind randomized controlled trial was held to assess the safety and efficacy of botulinum toxin type A (BTA) injection in hypertrophic scars (HS). Thirty patients with old scars (range: 1-15 years) were treated, with sides randomized to receive treatment with either BTA or 0.9% normal saline once monthly for three consecutive months. Scars were assessed using the Vancouver scar scale (VSS) along with digital photograph standardization. RESULTS: Twenty-one subjects completed the study. The mean VSS score for the BTA-treated half of the scars decreased from 7.29 ± 2.327 before injection to 5.33 ± 2.41 following injection which was highly significant (P = .01). For the control half, the mean VSS decreased insignificantly from 7.29 ± 2.327 before injection to 7.10 ± 2.234 following injection (P = .104). CONCLUSION: Clinical and cosmetic improvement was demonstrated significantly among the BTA-treated group. BTA can be an additional and useful tool for improving scar outcomes.
No takes yet. Share an insight, caveat, or question.
Elshahed et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: